Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W Jr, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Sch├╝tz E.

Clin Cancer Res. 2017 Sep 1;23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.

PMID:
28320758
2.

Wnt9A Induction Linked to Suppression of Human Colorectal Cancer Cell Proliferation.

Ali I, Medegan B, Braun DP.

Int J Mol Sci. 2016 Apr 2;17(4):495. doi: 10.3390/ijms17040495.

3.

Fatigue as a Driver of Overall Quality of Life in Cancer Patients.

McCabe RM, Grutsch JF, Braun DP, Nutakki SB.

PLoS One. 2015 Jun 12;10(6):e0130023. doi: 10.1371/journal.pone.0130023. eCollection 2015.

5.

Can quality of life assessments differentiate heterogeneous cancer patients?

McCabe RM, Grutsch JF, Nutakki SB, Braun DP, Markman M.

PLoS One. 2014 Jun 11;9(6):e99445. doi: 10.1371/journal.pone.0099445. eCollection 2014.

6.

The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy.

Vashi PG, Gupta D, Lammersfeld CA, Braun DP, Popiel B, Misra S, Brown KC.

Nutr J. 2013 Aug 14;12:118. doi: 10.1186/1475-2891-12-118.

7.

Prognostic value of changes in quality of life scores in prostate cancer.

Gupta D, Braun DP, Staren ED.

BMC Urol. 2013 Jul 10;13:32. doi: 10.1186/1471-2490-13-32.

8.

Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.

Gupta D, Braun DP, Staren ED, Markman M.

J Ovarian Res. 2013 Mar 8;6(1):17. doi: 10.1186/1757-2215-6-17.

9.

Effect of naturopathic and nutritional supplement treatment on tumor response, control, and recurrence in patients with prostate cancer treated with radiation therapy.

Braun DP, Gupta D, Birdsall TC, Sumner M, Staren ED.

J Altern Complement Med. 2013 Mar;19(3):198-203. doi: 10.1089/acm.2011.0657. Epub 2012 Oct 4.

10.

Longitudinal health-related quality of life assessment implications for prognosis in stage IV pancreatic cancer.

Braun DP, Gupta D, Staren ED.

Pancreas. 2013 Mar;42(2):254-9. doi: 10.1097/MPA.0b013e31825b9f56.

PMID:
22850626
11.

Association between changes in quality of life scores and survival in non-small cell lung cancer patients.

Gupta D, Braun DP, Staren ED.

Eur J Cancer Care (Engl). 2012 Sep;21(5):614-22. doi: 10.1111/j.1365-2354.2012.01332.x. Epub 2012 Feb 6.

PMID:
22309434
12.

Role of nutritional status in predicting the length of stay in cancer: a systematic review of the epidemiological literature.

Gupta D, Vashi PG, Lammersfeld CA, Braun DP.

Ann Nutr Metab. 2011;59(2-4):96-106. doi: 10.1159/000332914. Epub 2011 Dec 2. Review.

13.

The prognostic role of quality of life assessment in breast cancer.

Staren ED, Gupta D, Braun DP.

Breast J. 2011 Nov-Dec;17(6):571-8. doi: 10.1111/j.1524-4741.2011.01151.x. Epub 2011 Sep 4.

PMID:
21895846
14.

Quality of life assessment as a predictor of survival in non-small cell lung cancer.

Braun DP, Gupta D, Staren ED.

BMC Cancer. 2011 Aug 15;11:353. doi: 10.1186/1471-2407-11-353.

15.

Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer?

Braun DP, Gupta D, Grutsch JF, Staren ED.

Health Qual Life Outcomes. 2011 Aug 3;9:62. doi: 10.1186/1477-7525-9-62.

16.

Predicting survival in prostate cancer: the role of quality of life assessment.

Braun DP, Gupta D, Staren ED.

Support Care Cancer. 2012 Jun;20(6):1267-74. doi: 10.1007/s00520-011-1213-x. Epub 2011 Jun 28.

17.

The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer.

Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DF, Reynolds JL, Ansell CM, Oh EY, Daehler MA, Levin RD, Braun DP, Gupta D, Lis CG, Hrushesky WJ.

BMC Cancer. 2011 May 23;11:193. doi: 10.1186/1471-2407-11-193.

18.

Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer.

Vashi PG, Lammersfeld CA, Braun DP, Gupta D.

Nutr J. 2011 May 16;10:51. doi: 10.1186/1475-2891-10-51.

19.

Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology.

Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D.

Nutr J. 2010 Nov 23;9:60. doi: 10.1186/1475-2891-9-60.

20.

Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Gupta D, Lammersfeld CA, Vashi PG, Braun DP.

J Ovarian Res. 2010 Oct 12;3:22. doi: 10.1186/1757-2215-3-22.

Supplemental Content

Loading ...
Support Center